Shire reaches agreement with U.S. government, to record $57.5M charge in Q4 Shire announced that it has reached an agreement in principle to resolve the previously disclosed civil investigation into Shire's U.S. sales and marketing practices relating to Adderall XR, Vyanse and Daytrana. The investigation was led by the U.S. Attorney's Office for the Eastern District of Pennsylvania, and Shire disclosed the investigation in 2009. The agreement also addresses sales and marketing practices relating to Lialda and Pentasa pursuant to a subsequent voluntary disclosure made by Shire. Shire has recorded a $57.5M charge in Q4, comprised of the agreement in principle amount, interest and costs.
News For SHPG From The Last 14 Days
Check below for free stories on SHPG the last two weeks.